Related Experiment Video

Updated: May 24, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Virotherapy of neuroendocrine tumors

Magnus Essand1

  • 1Rudbeck Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. magnus.essand@igp.uu.se

Neuroendocrinology
|March 2, 2012
PubMed

Insights

Engineered oncolytic viruses, particularly adenoviruses, show promise for treating small intestinal neuroendocrine tumors (SI-NETs) liver metastases. These viruses can be engineered for targeted cancer cell infection and replication, offering a potential curative approach for advanced SI-NETs.

Area of Science:

  • Oncology
  • Virology
  • Biotechnology

Background:

  • Small intestinal neuroendocrine tumors (SI-NETs), or midgut carcinoids, frequently present with metastatic disease, particularly in the liver.
  • Current treatments for advanced SI-NETs are limited, highlighting the need for novel therapeutic strategies.

Purpose of the Study:

  • To review the potential of engineered oncolytic viruses, specifically adenoviruses, as a curative therapy for SI-NET liver metastases.
  • To explore the general application of oncolytic viruses in neuroendocrine tumor (NET) treatment.

Main Methods:

  • Focus on adenovirus as an oncolytic agent for SI-NET liver metastases.
  • Discussion of engineering viruses for selective NET cell targeting and replication.
  • Review of advantages and disadvantages of replicating oncolytic viruses in cancer therapy.

Main Results:

  • Engineered oncolytic viruses can be designed to exploit neuroendocrine cell biology for targeted therapy.
  • Adenoviruses offer a potential avenue for treating SI-NET liver metastases.

Conclusions:

  • Oncolytic viruses, especially adenoviruses, represent a promising therapeutic strategy for managing SI-NET liver metastases.
  • Further research into enhancing virus-based therapy efficacy is crucial for clinical application.

More Related Videos

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

Intranasal Delivery of Therapeutic Stem Cells to Glioblastoma in a Mouse Model09:57

Intranasal Delivery of Therapeutic Stem Cells to Glioblastoma in a Mouse Model

Published on: June 4, 2017

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...